TAK-411 for adults with CIDP
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new investigational drug called TAK-411 for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for people who have already responded to immunoglobulin therapy and are on a stable dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and weigh 330 pounds (150 kg) or less.
- You have typical CIDP (not a variant) and have responded well to immunoglobulin (IG) treatment before.
- Your CIDP has been active in the last 2 years, meaning symptoms got worse when IG was stopped or between doses.
- You are on a stable dose of intravenous immunoglobulin (IGIV) and have been for at least 3 months.
- You do not have other causes of nerve damage, recent blood clots, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if TAK-881 is as safe and effective as HYQVIA for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). You may join if you have been stable on immune globulin therapy and have certain disability levels.
This trial tests a new medication called TAK-188 for people with certain advanced solid tumors that have not responded to standard therapies, including checkpoint inhibitors. It aims to see if TAK-188 can help shrink or control the cancer.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
This trial tests nipocalimab (an antibody medicine) to improve symptoms and control activity in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. It may help reduce disease activity and disability, while checking safety.
This program offers continued access to the study drug TAK-881 for people with primary immunodeficiency diseases who have already completed a related study. It is designed for those who are benefiting from the treatment and have no safety concerns.
Hear when a new Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.